A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib in Healthy Adults
Latest Information Update: 04 Nov 2024
Price :
$35 *
At a glance
- Drugs Radotinib (Primary)
- Indications Chronic myeloid leukaemia; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Il-Yang Pharmaceutical
- 30 Oct 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 17 Jun 2024 New trial record